Inquiry Basket
Loading ......
Filter By Product Search for
MGMT
MGMT Full Name
O-6-methylguanine-DNA methyltransferase
MGMT Introduction
O-6-methylguanine-DNA methyltransferase (MGMT), also referred to as O6-alkylguanine DNA alkyltransferase (AGT), is a DNA repair enzyme that protects cells from the mutagenic and cytotoxic effects of alkylating agents. Encoded by the MGMT gene on chromosome 10q26.3, MGMT is a unique DNA repair protein that functions through a single-turnover, suicidal mechanism: it directly transfers the alkyl group from the O6 position of guanine (and to a lesser extent from the O4 position of thymine) to a cysteine residue (Cys145) within its own active site, restoring the DNA base in a single step without the need for excisional repair. This stoichiometric reaction irreversibly inactivates the MGMT protein, which is then ubiquitinated and degraded by the proteasome, earning MGMT the designation of a suicide enzyme.
Figure 1. Strcuture of MGMT.(Irfandi R, Santi S, Raya I, 2022)
Mechanism of Direct DNA Alkylation Repair
The MGMT repair mechanism is elegantly simple yet highly effective. The enzyme recognizes O6-alkylguanine lesions within double-stranded DNA, flips the damaged nucleotide out of the DNA helix into its active site pocket, and catalyzes the transfer of the alkyl adduct to the active site cysteine (Cys145). The active site employs a hydrogen-bonding network involving a conserved histidine (His146) and glutamate (Glu172) that activates the cysteine thiolate for nucleophilic attack on the alkyl group. Following alkyl transfer, a conformational change in the alkylated protein exposes a degron sequence that targets it for ubiquitin-mediated proteasomal degradation. MGMT expression is regulated primarily through epigenetic silencing via promoter CpG island hypermethylation, rather than through classical transcriptional regulatory mechanisms. This methylation status is a critically important biomarker in oncology, as MGMT promoter methylation status predicts responsiveness of glioblastoma to the alkylating chemotherapeutic agent temozolomide.
MGMT in Glioblastoma Therapy, Chemoresistance, and Pharmacological Modulation
MGMT is a central determinant of tumor resistance to alkylating chemotherapeutics, most notably temozolomide (TMZ) used in the treatment of glioblastoma multiforme (GBM) and other brain tumors. Tumors with an unmethylated, transcriptionally active MGMT promoter efficiently repair TMZ-induced O6-methylguanine lesions and are resistant to therapy, while patients with epigenetically silenced MGMT (methylated promoter) show significantly improved progression-free and overall survival. MGMT promoter methylation testing is now standard of care for treatment stratification in GBM. Pharmacological MGMT inhibitors, such as O6-benzylguanine (O6-BG) and lomeguatrib, have been developed to deplete MGMT activity and sensitize tumors to alkylating agents, though their clinical use has been limited by dose-limiting myelotoxicity resulting from sensitization of normal hematopoietic cells. Second-generation strategies include tumor-targeted delivery of MGMT inhibitors and gene therapy approaches to protect bone marrow stem cells from alkylation damage while allowing therapeutic sensitization of the tumor.
Alternate Names for MGMT
MGMT; O-6-methylguanine-DNA methyltransferase; methylated-DNA--protein-cysteine methyltransferase; methylguanine-DNA methyltransferase; O-6-methylguanine-DNA-alkyltransferase; O6-methylguanine-DNA methyltransferase; 6-O-methylguanine-DNA methyltransferase;
Loading ......
